Abstract
BackgroundKRAS G12C is a mutation that occurs in approximately 3 to 4% of patients with metastatic colorectal cancer. Monotherapy with KRAS G12C inhib......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
